Πέμπτη 10 Σεπτεμβρίου 2020

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide: Nonmetastatic, castration-resistant prostate cancer is defined by rising levels of serum prostate-specific antigen (PSA) and an absence of detectable metastases on conventional imaging in patients receiving androgen-deprivation therapy. Patients with nonmetastatic, castration-resistant prostate…


Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου